Cardiff University has an excellent track record of commercially exploiting the outcomes of its research. Forming a company to exploit University know-how or expertise is one of the routes available, and is supported through the Wales Spin-Out Programme. Licensing and royalty agreements — which enable businesses to use Cardiff research commercially — bring enormous benefits to a range of companies. Examples of recent successes are shown below along with current opportunities. If you are interested in obtaining further information please contact us.
A powerful new treatment for shingles will be one step closer after a multi-million pound deal on the US stock exchange.
US-based pharmaceutical company Inhibitex has agreed a merger with Fermavir Pharmaceuticals Inc, a spin-out company based on antiviral research patented at Cardiff University. The deal means that clinical trials can go ahead on FV-100, an anti-shingles drug discovered and developed by Professor Chris McGuigan, of Cardiff University’s School of Pharmacy.
- Biofusion Trade Sale of Cardiff Protides and Cardiff Biologicals
- Biofusion completes Cardiff University investment deals in Cardiff Biologicals and Cardiff Protides
- Spin-out’s £2 million fund-raising success
- Spin-out technology in £25m deal
Recently Licensed Technologies
Current Licensing Opportunities
For further information please contact the Technology Transfer Group: